purpos
sever
marker
eosinophil
inflamm
propos
predict
respons
asthma
treatment
howev
definit
criteria
treatment
decis
yet
establish
investig
potenti
use
rel
noninvas
biomark
eosinophilderiv
neurotoxin
edn
predict
favor
respons
budesonid
montelukast
common
treatment
children
asthma
method
young
children
year
old
enrol
random
parallel
openlabel
trial
criteria
elig
includ
symptomat
runin
period
serum
edn
sedn
level
ngml
posit
specif
immunoglobulin
e
hous
dust
mite
elig
patient
randomli
place
group
bi
group
receiv
budesonid
inhal
suspens
bi
mg
daili
mont
group
receiv
montelukast
mg
daili
inelig
patient
invit
receiv
montelukast
mg
daili
ob
group
treatment
period
week
result
asthma
control
day
increas
significantli
bi
mont
group
p
studi
period
signific
chang
sedn
bi
group
signific
decreas
mont
group
p
patient
ob
group
high
edn
level
ngml
show
signific
decreas
due
mont
treatment
p
rescu
medic
usag
significantli
decreas
bi
mont
group
p
conclus
edn
use
rel
noninvas
biomark
predict
respons
montelukast
budesonid
treatment
preschool
children
respons
recurr
wheez
multipletrigg
wheez
trial
registri
umin
clinic
trial
registri
chronic
airway
inflamm
hallmark
asthma
consequ
inhal
corticosteroid
icss
main
treatment
although
leukotrien
receptor
antagonist
ltra
also
antiinflammatori
properti
often
administ
especi
young
children
guidelin
clearli
state
icss
prefer
option
longterm
control
asthma
prefer
base
mainli
evid
clinic
trial
compar
mean
respons
treatment
control
group
howev
trial
demonstr
consider
interindividu
variabl
treatment
respons
icss
versu
ltra
import
clinician
collect
inform
better
guid
select
medic
like
achiev
favor
respons
patient
ie
tailormad
treatment
regimen
sever
marker
eosinophil
inflamm
atopi
elev
level
serum
immunoglobulin
e
ige
due
hous
dust
mite
hdm
dermatophagoid
pteronyssinu
dp
sensit
sputum
eosinophil
count
exhal
nitric
oxid
serum
eosinophil
cation
protein
ecp
suggest
predict
respons
icss
howev
definit
criteria
treatment
decis
still
establish
addit
characterist
airway
patholog
preschool
children
may
differ
older
children
adult
may
lead
differenti
treatment
respons
addit
ecp
elev
level
anoth
eosinophil
degranul
product
eosinophilderiv
neurotoxin
edn
note
asthmat
higher
level
also
found
asthma
exacerb
compar
healthi
patient
stabl
asthma
therefor
edn
suggest
key
marker
diseas
activ
asthma
eosinophilrel
diseas
date
publish
studi
compar
differenti
respons
type
antiinflammatori
therapi
name
icss
ltra
preschool
children
asthma
furthermor
clinic
marker
possibl
differenti
respons
defin
propos
studi
seek
use
rel
noninvas
marker
ie
serum
edn
sedn
predict
favor
respons
nebul
budesonid
montelukast
common
treatment
option
young
children
asthma
children
age
year
enrol
studi
asthma
heterogen
diseas
especi
difficult
diagnos
age
group
definit
asthma
use
base
global
initi
asthma
gina
japanes
pediatr
guidelin
major
inclus
criteria
follow
recurr
wheez
episod
within
year
least
one
confirm
physician
multipletrigg
wheez
common
cold
trigger
exercis
cri
laugh
improv
wheez
administr
inhal
oral
shortact
minor
inclus
criteria
includ
least
one
follow
parent
asthma
physiciandiagnos
atop
dermat
ad
physiciandiagnos
allerg
rhiniti
ar
physiciandiagnos
food
allergi
includ
studi
patient
must
major
criteria
least
one
minor
inclus
criteria
criteria
random
includ
patient
symptomat
runin
period
sedn
level
ng
ml
posit
specif
ige
hdm
immulit
iu
ml
exclus
criteria
includ
one
follow
patient
receiv
asthma
control
medic
icss
ltra
previou
month
chronic
lung
diseas
heart
kidney
diseas
congenit
diseas
patient
physician
regard
inappropri
studi
eg
attend
clinic
instruct
random
parallel
openlabel
trial
patient
met
enrol
criteria
enter
runin
period
shortact
need
particip
randomli
select
join
group
bi
group
receiv
budesonid
inhal
suspens
bi
mg
daili
week
mont
group
receiv
montelukast
mg
daili
oral
week
bi
administ
via
skyneb
medel
milan
itali
compressor
nebul
mouthpiec
older
children
face
mask
children
year
old
patient
inelig
trial
random
criteria
met
edn
ngml
andor
neg
specif
ige
hdm
yet
symptom
runin
period
invit
receiv
montelukast
mg
daili
base
recommend
japanes
guidelin
observ
week
exploratori
purpos
ob
group
parentscaregiv
particip
instruct
record
symptom
treatment
time
asthma
diari
patient
evalu
interv
fig
either
hospit
clinic
asthma
diari
check
determin
whether
stepup
therapi
need
per
gina
japanes
guidelin
comput
random
elig
patient
either
bi
mont
group
perform
howev
adjust
made
statist
similar
proport
patient
group
base
age
year
old
versu
year
old
sex
specif
ige
hdm
iuaml
versu
iuaml
edn
level
patient
measur
twice
week
runin
period
time
point
edn
measur
use
enzymelink
immunosorb
assay
elisa
follow
manufactur
protocol
mbl
woburn
usa
result
express
nanogram
per
millilit
ngml
elisa
detect
human
edn
minimum
detect
limit
ngml
maximum
detect
limit
ngml
crossreact
ecp
assay
run
duplic
mean
valu
use
statist
analys
initi
enrol
exhibit
asthma
upper
respiratori
infect
symptom
regular
visit
nasopharyng
swab
collect
total
rna
common
respiratori
virus
extract
identifi
use
multiplex
pcr
system
seeplex
ace
detect
seegen
seoul
korea
identifi
adenoviru
primari
outcom
number
asthma
control
day
acd
acd
defin
day
betaagonist
rescu
use
use
oral
corticosteroid
asthma
daytim
symptom
nighttim
awaken
unschedul
health
care
visit
emerg
depart
visit
hospit
asthma
school
absente
asthma
acd
group
bi
mont
compar
way
within
group
analys
compar
acd
begin
treatment
period
week
acd
point
week
group
analys
compar
acd
group
time
point
eg
bi
acd
week
versu
mont
acd
week
acd
valu
calcul
group
time
period
exampl
acd
week
calcul
runin
period
ie
week
acd
week
calcul
time
period
week
etc
first
comparison
use
analysi
varianc
anova
follow
sidak
multipl
comparison
test
second
comparison
use
wilcoxon
matchedpair
sign
rank
test
secondari
outcom
studi
compar
chang
sedn
patient
sedn
ngml
hdm
sensit
bi
mont
group
patient
whose
sedn
ngml
sensit
hdm
ob
group
serum
taken
patient
week
sedn
measur
valu
use
week
term
pre
random
patient
either
bi
mont
group
also
sedn
measur
week
term
post
pre
post
sedn
level
compar
patient
use
wilcoxon
matchedpair
sign
rank
test
anoth
secondari
outcom
studi
chang
rescu
medic
usag
treatment
comparison
done
way
within
group
bi
mont
usag
runin
week
compar
usag
end
treatment
period
week
subject
group
analyz
studi
period
week
determin
chang
usag
usag
bi
group
compar
usag
mont
group
time
point
week
endpoint
stratifi
analysi
perform
base
viru
type
detect
within
group
analys
acd
multipl
time
point
entir
studi
period
week
compar
use
anova
follow
sidak
multipl
comparison
test
done
bi
mont
group
betweengroup
analys
acd
bi
versu
mont
group
done
use
wilcoxon
matchedpair
sign
rank
test
within
group
analys
treatment
effect
compar
pre
measur
runin
period
week
post
measur
week
measur
chang
sedn
group
bi
mont
ob
done
use
wilcoxon
matchedpair
sign
rank
test
group
subgroup
accord
presenc
absenc
viru
chang
sedn
treatment
pre
post
analyz
use
statist
test
rescu
medic
usag
within
group
bi
mont
group
also
compar
data
normal
distribut
present
mean
valu
unless
otherwis
note
p
valu
consid
statist
signific
fig
anova
follow
bonn
ferroni
multipl
comparison
test
use
determin
statist
differ
demograph
data
among
group
ie
bi
mont
ob
tabl
age
p
proport
ad
p
ob
group
significantli
lower
compar
group
age
differ
ob
group
group
expect
subject
bi
mont
group
agematch
demograph
variabl
statist
similar
among
group
laboratori
data
entri
found
tabl
hdmige
send
level
ob
group
significantli
lower
compar
group
expect
includ
ob
group
patient
sedn
level
ngml
sensit
hdm
acd
acd
increas
significantli
group
p
begin
studi
week
end
studi
week
howev
compar
acd
group
time
point
signific
differ
fig
bi
budesonid
inhal
suspens
mont
elig
receiv
montelukast
ob
elig
receiv
montelukast
age
ob
group
significantli
lower
p
atop
dermat
significantli
less
p
signific
chang
sedn
bi
group
fig
signific
decreas
found
mont
group
p
fig
ob
group
divid
low
edn
ngml
fig
high
edn
ngml
fig
patient
high
edn
exhibit
signific
decreas
due
mont
treatment
p
regardless
hdm
sensit
fortyfour
studi
subject
posit
viru
test
tabl
treatment
group
bi
mont
subgroup
accord
virusposit
measur
sedn
pre
post
chang
sedn
compar
virusposit
neg
subject
bi
mont
group
significantli
larger
virusneg
mont
subgroup
supplementari
fig
mean
also
larger
virusnag
bi
subgroup
statist
signific
supplementari
fig
chang
acd
differ
virusposit
neg
subgroup
bi
supplementari
fig
mont
supplementari
fig
group
anoth
secondari
outcom
studi
chang
rescu
medic
usag
treatment
comparison
done
way
within
group
bi
mont
usag
runin
week
compar
usag
end
treatment
period
week
subject
group
analyz
studi
period
week
week
determin
chang
usag
usag
bi
group
compar
usag
mont
group
time
point
week
signific
decreas
p
rescu
medic
usag
within
group
bi
mont
subject
group
analyz
studi
period
week
p
howev
signific
differ
found
compar
usag
bi
group
mont
group
studi
clearli
demonstr
preschool
children
respons
recurr
wheez
multipletrigg
wheez
high
edn
level
hdm
sensit
respond
well
montelukast
budesonid
expect
montelukast
treatment
significantli
reduc
sedn
level
unexpectedli
bi
treatment
treatment
also
result
signific
decreas
rescu
medic
usag
treatment
period
term
clinic
outcom
montelukast
effect
budesonid
biomarkerdefin
ie
mite
sensit
eosinophil
asthma
subpopul
preschool
asthmat
asthma
heterogen
diseas
mani
phenotyp
recognit
high
edn
hdmsensit
phenotyp
exhibit
favor
respons
standard
asthma
treatment
import
patient
screen
elig
nearli
half
found
phenotyp
consider
elev
level
edn
eosinophil
degranul
product
found
symptomat
asthma
would
suggest
airway
inflamm
character
increas
number
eosinophil
also
increas
airway
eosinophil
degranul
therefor
suggest
secretori
activ
eosinophil
combin
concentr
eosinophil
propens
releas
degranul
product
may
key
marker
diseas
activ
accur
assess
eosinophil
degranul
product
edn
edn
releas
almost
exclus
eosinophil
therefor
chang
edn
level
would
direct
reflect
chang
eosinophil
inflamm
signific
chang
edn
level
diseas
phase
note
previou
studi
edn
may
therefor
use
predict
therapeut
outcom
welcom
addit
clinician
abil
effect
treat
monitor
asthma
demonstr
studi
montelukast
treatment
significantli
reduc
elev
edn
level
mont
group
also
shown
asthma
studi
even
patient
postrsv
bronchiol
recurr
wheez
among
subject
exclud
main
studi
group
ob
group
subgroup
hdm
sensit
elev
edn
experienc
reduct
edn
level
well
montelukast
chosen
treatment
ob
group
report
ic
less
effect
nonatop
popul
furthermor
clinic
experi
montelukast
prefer
ic
physician
patient
korea
japan
treatmentrel
reduct
edn
level
may
yield
actual
patient
benefit
studi
subject
receiv
montelukast
treatment
week
signific
increas
number
acd
compar
begin
studi
also
statist
similar
number
acd
time
point
week
compar
receiv
bi
treatment
bi
group
interest
find
consid
recent
cochran
review
studi
directli
compar
safeti
efficaci
antileukotrien
icss
monotherapi
found
ic
treatment
superior
number
respect
includ
symptomfre
day
howev
note
sampl
size
calcul
done
studi
point
discuss
studi
limit
section
bi
group
also
show
signific
increas
acd
treatment
period
previou
asthma
ad
studi
sedn
level
correl
well
symptom
score
known
eosinophil
releas
edn
degranul
product
activ
particular
peripher
blood
eosinophil
found
releas
approxim
total
intracellular
edn
furthermor
sedgwick
et
al
demonstr
intracellular
edn
also
increas
asthmat
patient
ecp
montelukast
ltra
capabl
bind
cystein
leukotrien
cyslt
receptor
express
eosinophil
disrupt
autocrin
releas
cyslt
induc
eosinophil
degranul
lead
releas
number
mediat
includ
edn
ecp
cyslt
may
explain
reduct
edn
level
mont
group
patient
ob
group
high
edn
level
corticosteroid
treatment
may
may
elimin
cytokineprim
ednincreas
longersurviv
eosinophil
result
decreas
edn
level
observ
signific
decreas
edn
level
budesonid
treatment
studi
contrari
initi
hypothesi
budesonid
would
also
reduc
edn
level
may
budesonid
ic
act
local
wherea
montelukast
act
system
eosinophil
develop
princip
bone
marrow
recruit
circul
migrat
inflammatori
site
airway
particip
immunolog
process
activ
eosinophil
releas
edn
granular
protein
chang
granular
protein
level
signal
chang
turnov
activ
eosinophil
taken
togeth
eosinophil
product
recruit
activ
system
process
patient
studi
also
test
viru
infect
well
known
respiratori
viral
infect
major
caus
asthma
exacerb
children
detect
viru
half
treat
subject
reduct
sedn
level
significantli
larger
virusneg
subgroup
mont
group
indic
viru
infect
may
hinder
effect
montelukast
supplementari
fig
howev
edn
level
still
significantli
decreas
virusposit
mont
subgroup
data
shown
may
result
level
improv
acd
virusposit
neg
subgroup
supplementari
fig
studi
limit
includ
openlabel
design
could
affect
result
placebo
effect
measur
secondari
outcom
ie
sedn
level
rescu
medic
usag
done
time
begin
studi
baselin
second
time
end
studi
may
benefici
measur
serial
patient
recruit
differ
healthcar
center
may
introduc
spectrum
bia
affect
studi
result
sampl
size
calcul
done
number
elig
patient
studi
n
may
small
accur
assess
associ
predictor
ie
elev
sedn
posit
ige
hdm
outcom
signific
improv
acd
sedn
rescu
medic
follow
treatment
recent
metaanalys
green
et
al
studi
other
bolster
hypothesi
treatmentbas
eosinophil
indic
efficaci
ie
reduc
frequenc
sever
exacerb
treatment
base
clinic
symptom
tradit
object
measur
lung
function
peak
expiratori
flow
spirometri
tailor
patient
treatment
base
direct
object
measur
airway
inflamm
result
significantli
less
frequent
sever
asthma
exacerb
consequ
trend
toward
fewer
asthmarel
hospit
admiss
know
inflammatori
profil
clinic
categor
patient
develop
clearer
phenotyp
asthma
patient
appear
contribut
improv
asthma
care
use
accur
biomark
eosinophil
inflamm
manag
asthma
may
produc
even
better
result
suggest
mani
studi
edn
accur
biomark
eosinophil
number
percentag
futur
studi
edn
biomark
diagnosi
treatment
monitor
condit
associ
airway
inflamm
recurr
wheez
multipletrigg
wheez
asthma
need
